CEL-SCI Corporation(CVM)Earnings, Financials & Key RatiosCEL-SCI Corporation (CVM) stock price & volume — 10-year historical chart
Investment Thesis • Updated 2026Q2
the company's precarious liquidity position, evidenced by a current ratio of 0.60 and a persistent lack of recurring revenue, suggests a high probability of further shareholder dilution.
CEL-SCI Corporation (CVM) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
CEL-SCI Corporation (CVM) EPS & revenue vs analyst estimates — last 4 quarters
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 15, 2026 | $1.35 | — |
| Q1 2026 | Feb 17, 2026 | $0.68 | — |
| Q1 2026 | Jan 12, 2026 | $2.70 | — |
| Q3 2025 | Aug 14, 2025 | $1.36 | — |
Recent stock market news and headlines for CEL-SCI Corporation (CVM)
VIENNA, Va.--(BUSINESS WIRE)---- $CVM #BIO2026--CEL-SCI and Saudi Amarox Hold Strategic Agreement Signing Ceremony at BIO 2026, Advancing U.S.–Saudi Cooperation in Cancer Care.
VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI announces closing of offering.
VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI advances Multikine immunotherapy for Head and Neck Cancer through dual U.S. registration study and Saudi market entry strategy.
Key metrics vs top competitors for CEL-SCI Corporation (CVM)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $1.11 | $7.63M | -0.18 | — | — | -176.32% | — | |
| $38.85 | $7.98B | -14.03 | — | — | -68.16% | — | |
| $74.96 | $8.89B | 29.28 | 37.55% | 23.13% | 126.27% | — | |
| $63.65 | $1.24B | -6.54 | -43.89% | -284.18% | -87% | — | |
| $8.75 | $2.03B | 14.58 | 19.63% | 32.43% | 38.97% | — | |
| $8.88 | $1.46B | 3.50 | 64.69% | -14.73% | — | — |
CEL-SCI Corporation (CVM) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
CEL-SCI Corporation (CVM) SEC filings — annual & quarterly reports (10-K, 10-Q)
May 14, 2026·SEC
May 13, 2026·SEC
Nov 24, 2025·SEC
Get notified when CVM posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
CEL-SCI Corporation (CVM) stock FAQ — growth, dividends, profitability & financials explained
CEL-SCI Corporation (CVM) reported a net loss of $22.7M for fiscal year 2025.
CEL-SCI Corporation (CVM) has a return on equity (ROE) of -176.3%. Negative ROE indicates the company is unprofitable.
CEL-SCI Corporation (CVM) had negative free cash flow of $16.7M in fiscal year 2025, likely due to heavy capital investments.
